Hammersmith Hospital 1902

industry:
Hospital
Nationality:
British
based:
Hammersmith, Hammersmith and Fulham, London, Greater London, England, United Kingdom

Royal Postgraduate Medical School attached to the hospital from 1931-1997 when it became part of Imperial College Medical School; Address : Du Cane Road, London, W12 0HS; Renowned for clinical research

Related Objects

Artificial kidney machine, France, 1955

Cambridge electrite direct-writing electrocardiograph machine
Patient information letter inviting participation in an expanded STI571 clinical trial issued to Doreen Eggleton being treated for Chronic Myeloid Leukaemia (CML), by Hammersmith Hospital in 2001. The letter is titled: 'An expanded access protocol of (clinical trial) STI571 in patients with Chronic myeloid leukaemia (CML) who are hematologically or cytogentically resistant or refractory to Interferon-Alpha or intolerant of Interferon-Alpha'.

Patient information about expanding the UK clinical trial of Glivec (imatinib), 2001
Yellow emergency contact card given to Doreen Eggleton to keep on her in case of a medical emergency, when on the first UK clinical trial (Novartis STI 571 0113) of the targeted drug Glivec (Imatinib) for the treatment of Chronic Myeloid Leukaemia (CML), a blood cancer, issued by Hammersmith Hospital in 2001, donated in 2023.

Emergency contact card given to a patient on the first UK trial of the drug Glivec (imatinib) for treatment of Chronic Myeloid Leukaemia (CML), issued by Hammersmith Hospital, 2001
Patient information letter titled 'Background information and current status of imintib mesylate - clinical usage and licensing (also known as STI571, Glivec, Gleevec)', issued to Doreen Eggleton being treated for Chronic Myeloid Leukaemia (CML), by Hammersmith Hospital, dated August 2001. Summarising information about the Glivec (imatinib) drug trials, cost of the drug made by Novartis, and actions leading to the drug becoming available on the NHS.

Patient information letter about the targeted cancer drug Glivec being made available on the NHS, 2001.
Pink slip of paper recording the diagnosis of Chronic Myeloid Leukaemia (CML) written down and given to Doreen Eggleton by her consultant on 18th December 1998, when Doreen was first informed about her disease, donated in 2023.

Pink slip of paper recording the diagnosis of Chronic Myeloid Leukaemia (CML) given to Doreen Eggleton in 1998.
Patient information letter inviting participation in the STI571 clinical trial of the drug Glivec (imatinib) in adult patients patients with Chronic Myeloid Leukemia (CML), issued to Doreen Eggleton being treated for CML, issued by Hammersmith Hospital in 2001.

Patient information about UK clinical trial of Glivec (imatinib), 2001
Patient information documents related to the Co-vax Covid-19 research study (CML-CO-VAX - Seroprotection against SARS-CoV-2 in Chronic Myeloid Leukaemia (CML) patients receiving TKI therapy), inviting CML patient Doreen Eggleton to participate, issued by Imperial College Healthcare NHS Trust, 30th July 2022. Includes schedule for vaccination and assessment tests.

Patient information letter relating to Co-vax Covid-19 research study, 2021
Patient appointment card issued to Doreen Eggleton (married name Short) listing appointments during treatment for Chronic Myeloid Leukaemia (CML), issued by Hammersmith hospital NHS trust, 1998-2001.

Patient appointment card used by a patient treated for Chronic myeloid leukaemia, 1998-2001
Medical letter documenting the diagnosis and treatment of Doreen Eggleton from her first diganosis of Chronic Myeloid Leukaemia (CML) in November 1998, to her enrollment on the first UK clinical trial of Glivic (imatinib) trials in 2001, and documenting the gradual dose reduction of this drug in subsequent years to reduce side effects including swelling and abdominal pain, dated 2021.

Medical letter detailing patient's treatment for Chronic myeloid leukaemia, 2021
Consent form to participate in the STI571 clinical trial of the targeted therapy Glivec (imatinib) in patients with Chronic Myeloid Leukaemia (CML), signed by Doreen Eggleton, 3rd October 2001. This was the copy of consent kept by the patient.

Patient consent form relating to a UK clinical trial of Glivec (Imatinib), 2001

See more related objects